Navigation Links
Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer -

LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- Response Genetics, Inc. today announced that positive Phase III clinical data published in the July 1 issue of the Journal of Clinical Oncology suggests that low expression of the biomarker Excision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsies with advanced non-small cell lung cancer (NSCLC) predicts for sensitivity to cisplatin-based chemotherapy. ERCC-1 is an enzyme involved in repair of DNA strand breaks such as those caused by cisplatin. The analysis of ERCC-1 levels in this study was conducted by Response Genetics using its RGI-1 technology. Data from previous studies published by the Company in Clinical Cancer Research 2002 and Annals of Oncology 2006 showing that ERCC-1 was associated with tumor sensitivity to cisplatin formed the basis for the present study. This is the first prospective study using a biomarker to predict chemotherapy response in lung cancer. These findings support the use of measurement of ERCC-1 for individualizing therapies for lung cancer patients.

The Phase III multicenter, randomized study was designed to determine the overall response rate (complete plus partial responses) of patients with stage IIIb or IV NSCLC to cisplatin-based therapy by determining levels of the biomarker ERCC-1 mRNA in their paraffin-embedded tissue biopsy before administering treatment. Patients were prospectively assigned treatment to a cisplatin or non-cisplatin-based chemotherapy depending on whether the ERCC-1 gene expression in their tumor sample was above or below a specific threshold. Patients were assigned to one of two arms in this trial. The control arm consisted of all patients receiving cisplatin-based therapy. Patients in the "genotypic" arm were separated by levels of ERCC-1. Cisplatin-based therapy (docetaxel/cisplatin) was assigned to patients with low
'"/>




Page: 1 2 3 4

Related medicine technology :

1. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
2. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
5. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
6. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
7. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
8. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
9. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
10. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
11. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
Post Your Comments:
(Date:3/6/2015)... ST. PAUL, Minn. , March 6, 2015 /PRNewswire/ ... benefit manager serving more than 26 million members, today ... and Drug Administration,s (FDA) approval of the first biosimilar ... U.S. Food and Drug Administration (FDA) approval of Sandoz,s ... of all cancer patients, is a major milestone in ...
(Date:3/6/2015)... 2015  Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in ... cancer, today announced that James A. Joyce , ... corporate overview at the 27th Annual ROTH Conference on ... was previously scheduled to present at 5:30 pm Pacific ... held at The Ritz-Carlton Hotel in Laguna ...
(Date:3/6/2015)... , March 6, 2015  Par Pharmaceutical Companies, ... conference call on Friday, March 13, 2015 at ... operations for the fourth quarter and full year ... and currently makes certain financial information available to ... and Exchange Commission and will make certain other ...
Breaking Medicine Technology:Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 2Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 3Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2
... Conn., Oct. 6 The Hedgeye Risk Management Healthcare team, led ... Conference Call, "Aging of America: Demographics of Demand and Profits in ... long tail of demographics, why 1994-2002 was so good, and why ... device demand, and the outlook for hip, knee, and spine device ...
... Oct. 6 Roxane Laboratories, Inc. announced today ... (ANDA) for Losartan Potassium Tablets USP, 25mg, 50mg ... Hydrochlorothiazide Tablets, 50mg/12.5mg and 100mg/25mg by the U.S. ... for immediate shipment to wholesalers and pharmacies nationwide. ...
Cached Medicine Technology:Aging of America: Demographics of Demand and Profits in Healthcare 2Roxane Laboratories, Inc. Announces the Launch of Losartan Potassium Tablets USP and Losartan Potassium and Hydrochlorothiazide Tablets 2
(Date:3/6/2015)... (PRWEB) March 06, 2015 Ticket Down is ... Levi's® Stadium in Santa Clara, California. This state-of-the-art ... hosted a plethora of exciting events. , The “Kick the ... his popular summer tour to the west coast and Levi’s ... facility will take place on August 29 and fans of ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Follow ... as the pharmacokinetics of a drug refers to testing ... compound inside an organism. When toxicity studies are clubbed ... ADMET or ADME/Tox. Increasing focus on lowering costs and ... ADME-toxicology testing worldwide. The traditional drug development model uses ...
(Date:3/6/2015)... Parents need to start the discourse ... use disorders. School programs like DARE, or Drug Abuse ... or Narcotics Overdose Prevention and Education has already impacted ... News on Feb. 27th. As teens continue to ... drug prevention proponents are lobbying Florida to pass The ...
(Date:3/6/2015)... 06, 2015 Johnson & Johnson and ... on March 5, 2015 in Superior Court in the ... documents, a jury of 12 awarded Mrs. Perry $700,000 ... implanted with an Ethicon TVT Abbrevo plastic sling for ... three women also awarded $5 million in punitive damages. ...
(Date:3/6/2015)... Washington, DC (PRWEB) March 06, 2015 ... the nation’s only comprehensive source for key trends and ... specialty spend, medical injectables. Executives from Magellan Rx Management ... Pharmacy Trend Report: Discover Your Hidden Specialty Drug Spend,” ... Atlantic Information Services, Inc. , Specialty drug spend makes ...
Breaking Medicine News(10 mins):Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 3Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2
... is due to intensive care overuse or underuse , FRIDAY, ... United States are nearly five times more likely to spend ... in England, finds a new study, and U.S. patients over ... the ICU when they die. , That,s the conclusion of ...
... Length of labor and intensity vary among ethnic groups, ... Asian women experience less labor pain than other women, ... influenced by many different factors but are difficult to ... Pamela Flood, of the anesthesia department at Columbia University, ...
... Oct. 30 Qualsec (OTC Bulletin Board: QLSZ), which ... has signed an agreement with Seamless Corporation (OTC Bulletin ... part of the arrangement, VitaminSpice products will sell through ... retail offerings and other products will be co-marketed in ...
... Therap Services is hosting its 4th annual National ... 2010. Therap provides electronic documentation and communication ... developmental disabilities. Therap complies and helps providers comply ... , Provider Administrators are senior positions such ...
... With the rapidly increasing problem of cardiovascular (CVD) disease ... raise awareness of risk factors. The European Society of ... adopt an integrated approach to CVD management, through important ... more prevalent in India and China than in all ...
... says former star major league pitcher , FRIDAY, Oct. 30 ... hand. In less than a second, it curves and then ... curveball, when thrown correctly, is one of baseball,s most daunting ... so great have sworn that the ball seems to have ...
Cached Medicine News:Health News:Patients More Likely to Die While in ICU in U.S. Than in England 2Health News:Asians Seem to Suffer Less During Childbirth 2Health News:VitaminSpice Signs MOU With Seamless Corp. for Sale of VitaminSpice Product Line on the Seamless Websites 2Health News:VitaminSpice Signs MOU With Seamless Corp. for Sale of VitaminSpice Product Line on the Seamless Websites 3Health News:Therap Services to Host Conference on Electronic Documentation, Electronic Signatures and Electronic Health Records for the Developmental Disabilities Community 2Health News:ESC events in Asia tackle management of diabetes and cardiovascular disease 2Health News:ESC events in Asia tackle management of diabetes and cardiovascular disease 3Health News:Scientist Throws Curve Into Breaking-Ball Debate 2Health News:Scientist Throws Curve Into Breaking-Ball Debate 3
... Electronic Medical Office (EMO) truly built for ... the unique needs of your practice. The ... electronic record system (EMR, EHR, and EPR), ... a new level of efficiency and performance. ...
... This program module functions stand alone. ... of the ophthalmicsuite product. The ASC module ... used in ophthalmic surgical specialty. Cataract, cosmetic, ... module. The ASC forms are adapted to ...
... is the perfect solution to assist you in ... control of your practice through the creative use ... pencil. No more impatient clients waiting to see ... old patient records. No more illegible handwriting on ...
... patient care reports for cardiology and ... reporting and documentation tool, physicians can ... H&P, labs, medications, and procedural details. ... with an e-signature, and distributed at ...
Medicine Products: